The toxicity of the RNA CGG repeats in FXTAS
The toxicity of the RNA CGG repeats in FXTAS
批准号:
8897690
负责人:
LUBOV T TIMCHENKO
金额:
$13.55万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-09-01 至 2016-08-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Fragile X-associated Tremor/Ataxia Syndrome (FXTAS) is a progressive neurodegenerative disease characterized by tremor with ataxia, brain atrophy and cognitive defects. FXTAS is caused by CGG expansions, varying in the length from ~55 to 200 repeats (CGG55-200), in the 5' UTR of the FMR1 gene. The CGG expansions more than 200 repeats in the same gene cause the Fragile X Syndrome (FXS), an intellectual disability, distinct from FXTAS. Long CGG expansions silence the transcription of the FMR1 gene; while short expansions elevate the transcription of the FMR1. Numerous models show that the FMR1 mRNA with CGG55-200 repeats or RNA CGG55-200 repeats outside of the FMR1 mRNA cause neurodegeneration. The main pathologic feature of FXTAS is the formation of the ubiquitin (Ub)-positive inclusions that contain the proteasome and several RNA-binding proteins. However, the role of the Ub- proteasome system and RNA-binding proteins in the FXTAS pathology is not understood. The primary targets of the RNA CGG repeats also remain unknown. Previous work in my lab was focused on the mechanisms for Myotonic Dystrophies type 1 and type 2 which are caused by RNA CUG and CCUG repeats. In the course of these studies, we have found that CUG and CCUG repeats alter RNA metabolism by interaction with different RNA-binding proteins and by formation of soluble and precipitated RNA-protein complexes (RPCs). CUG and CCUG RNAs form soluble complexes with RNA-binding protein, CUGBP1, increasing CUGBP1 stability. CCUG repeats also affect protein degradation via formation of large RPCs, containing the proteasome and stress-related proteins. We propose that, similar to DM, short (55-200) RNA CGG repeats form soluble and precipitated RPCs. We suggest that soluble rCGG-RPCs might contain RNA-binding proteins such as CUGBP1, Pur� and hnRNP A2/B1, affecting their function. In support of this hypothesis, we have found that CUGBP1 is increased in brains of FMR1-CGG98 knock in mice. It is known that the precipitated rCGG repeats (foci) bind Sam68, MBNL1 and hnRNP G. We suggest that the excessive binding of these proteins to the precipitated RPCs may attract the proteasome leading to the Ub-positive inclusions. The main hypothesis of this application is that the brain atrophy and neurodegeneration in FXTAS is due to: (1) misregulation of RNA processing by RNA-binding proteins bound in soluble and precipitated RPCs; and (2) due to altered protein degradation. To determine the role of these toxic events in the FXTAS pathology, we propose to identify the primary targets of the rCGG100 and the FMR1-CGG90 RNAs using a tet-regulated cell model (Aim 1). The role of elevation of CUGBP1 in the neurodegeneration in vivo will be determined in rCGG90 transgenic and FMR1-CGG98 knock in mice of different age (Aim 2). These studies will help to identify the molecular mechanism of FXTAS and will provide a background for the development of therapy for FXTAS.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CNS in Congenital DM1: Pathogenesis and Therapeutic Opportunities
-
批准号:10089488
-
项目类别:
-
资助金额:$35.95万
-
财政年份:2020
-
负责人:LUBOV T TIMCHENKO
-
依托单位:
CNS in Congenital DM1: Pathogenesis and Therapeutic Opportunities
-
批准号:10553142
-
项目类别:
-
资助金额:$35.56万
-
财政年份:2020
-
负责人:LUBOV T TIMCHENKO
-
依托单位:
GSK3 beta study in patients with Myotonic Dystrophy 1
-
批准号:10593112
-
项目类别:
-
资助金额:$20.2万
-
财政年份:2019
-
负责人:LUBOV T TIMCHENKO
-
依托单位:
GSK3 beta study in patients with Myotonic Dystrophy 1
-
批准号:10326843
-
项目类别:
-
资助金额:$29.7万
-
财政年份:2019
-
负责人:LUBOV T TIMCHENKO
-
依托单位:
GSK3 beta study in patients with Myotonic Dystrophy 1
-
批准号:10087889
-
项目类别:
-
资助金额:$41.8万
-
财政年份:2019
-
负责人:LUBOV T TIMCHENKO
-
依托单位:
Inhibition of GSK3 beta as potential therapy for DM1
-
批准号:8930071
-
项目类别:
-
资助金额:$19.88万
-
财政年份:2014
-
负责人:LUBOV T TIMCHENKO
-
依托单位:
Inhibition of GSK3 beta as potential therapy for DM1
-
批准号:8635126
-
项目类别:
-
资助金额:$17.16万
-
财政年份:2014
-
负责人:LUBOV T TIMCHENKO
-
依托单位:
The toxicity of the RNA CGG repeats in FXTAS
-
批准号:8442154
-
项目类别:
-
资助金额:$19.56万
-
财政年份:2012
-
负责人:LUBOV T TIMCHENKO
-
依托单位:
The toxicity of the RNA CGG repeats in FXTAS
-
批准号:8536413
-
项目类别:
-
资助金额:$9.11万
-
财政年份:2012
-
负责人:LUBOV T TIMCHENKO
-
依托单位:
Mechanisms of decay of toxic CUGn RNA in DM1 patients
-
批准号:7620081
-
项目类别:
-
资助金额:$7.68万
-
财政年份:2008
-
负责人:LUBOV T TIMCHENKO
-
依托单位:
Myotonic Dystrophy Type 2
-
批准号:7629576
-
项目类别:
-
资助金额:$28.42万
-
财政年份:2005
-
负责人:LUBOV T TIMCHENKO
-
依托单位:
Myotonic Dystrophy type 2
-
批准号:8664348
-
项目类别:
-
资助金额:$34.36万
-
财政年份:2005
-
负责人:LUBOV T TIMCHENKO
-
依托单位:
Myotonic Dystrophy type 2
-
批准号:8481517
-
项目类别:
-
资助金额:$33.31万
-
财政年份:2005
-
负责人:LUBOV T TIMCHENKO
-
依托单位:
Myotonic Dystrophy type 2
-
批准号:8104855
-
项目类别:
-
资助金额:$35.06万
-
财政年份:2005
-
负责人:LUBOV T TIMCHENKO
-
依托单位:
Myotonic Dystrophy Type 2
-
批准号:6960868
-
项目类别:
-
资助金额:$28.22万
-
财政年份:2005
-
负责人:LUBOV T TIMCHENKO
-
依托单位:
Myotonic Dystrophy Type 2
-
批准号:7092197
-
项目类别:
-
资助金额:$29.0万
-
财政年份:2005
-
负责人:LUBOV T TIMCHENKO
-
依托单位:
Myotonic Dystrophy type 2
-
批准号:8303445
-
项目类别:
-
资助金额:$35.06万
-
财政年份:2005
-
负责人:LUBOV T TIMCHENKO
-
依托单位:
Myotonic Dystrophy Type 2
-
批准号:7241575
-
项目类别:
-
资助金额:$28.16万
-
财政年份:2005
-
负责人:LUBOV T TIMCHENKO
-
依托单位:
Myotonic Dystrophy Type 2
-
批准号:7436135
-
项目类别:
-
资助金额:$27.6万
-
财政年份:2005
-
负责人:LUBOV T TIMCHENKO
-
依托单位:
The Role of RNA-Binding Proteins in Myogenesis
-
批准号:6890482
-
项目类别:
-
资助金额:$28.29万
-
财政年份:2003
-
负责人:LUBOV T TIMCHENKO
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于合成生物标志物的超多重RNA数字化检测平台用于肿瘤精准诊断和分期评估
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:程子译
-
依托单位:
RNA m6A修饰通过调控FDX1介导的铜死亡参与补阳还五汤抗脑缺血再灌注损伤作用机制的研究
-
批准号:2026JJ81091
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:刘亮
-
依托单位:
免标记CRISPR-RNA适配体与门逻辑分子诊断新方法研究
-
批准号:2026JJ50010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:应站明
-
依托单位:
Dead-box解旋酶DDX23通过调控RNA高级结构促进肝癌细胞恶性生物学行为的分子机制研究
-
批准号:JCZRLH202600588
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
基于基因编辑技术解析丹酚酸B靶向SAMHD1调控心肌线粒体RNA稳态干预心衰的分子机制研究
-
批准号:JCZRLH202601084
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
RNA 结合蛋白HuR与VEGF-D联合调控舌鳞癌侵袭及转移机制的研究
-
批准号:2026JJ80684
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:龚攀
-
依托单位:
基于异质人群多源数据识别单细胞 RNA数量性状风险位点的统计学方法研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:蔡铭轩
-
依托单位:
uN2CpolyG蛋白经ALYREF蛋白介导RNA转运异常在神经元核内包涵体病发病中的作用及机制研究
-
批准号:2026JJ60587
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:张思哲
-
依托单位:
病毒非编码RNA多样性图谱构建及其生物发生与致病机制研究
-
批准号:2026JJ60389
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:傅萍
-
依托单位:
核糖核酸酶RNase E与其抑制因子RebA通过液-液相分离调控蓝藻RNA代谢的分子机制
-
批准号:JCZRQNB202600879
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位: